Nephrocare Health Services Share Price Target 2025, 2026, 2030, 2040, 2050
Nephrocare Health Services is a well-known company that provides complete kidney care. It offers dialysis in its clinics, dialysis at home, mobile dialysis, wellness support, help from diagnosis to treatment, and small pharmacy services. The company is one of the biggest dialysis providers in India and Asia, with many clinics across the country, especially in smaller cities and towns, and it also has centres in countries like the Philippines, Uzbekistan, and Nepal. The company uses its own easy and safe systems, like RenAssure for good-quality care and Renova, a cloud-based tool for cleaning dialysers, to make sure patients get safe, smooth, and comfortable treatment.
What is the Nephrocare Health Services Ltd?
Nephrocare Health Services was established in 2009 in Hyderabad, Telangana, and was founded by Vikram Vuppala and Kamal Shah. It is a big healthcare company that provides simple and safe care for kidney and related issues. The company runs many dialysis clinics in India and other countries, and offers services like regular dialysis, home dialysis, mobile dialysis, wellness support, and small in-house pharmacies. It also works with many popular hospitals to run their dialysis units, and its easy and flexible way of growing helps it reach more people in both big cities and smaller towns.
It is a healthcare company that focuses on kidney care. It runs a big network of dialysis centres and kidney-care facilities to provide treatment for people with chronic kidney disease. The company’s goal is to make good-quality treatment available to everyone, no matter where they live or how much money they have. It focuses on patient-friendly services that combine medical expertise, modern equipment, and caring support. In 2025, its share price target would be ₹610, as per stock market analysts.
Its share price would be between ₹300 to ₹610 in 2025, as per stock market analysts.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2025 | 300 | 610 |
| महीना | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| दिसम्बर | 300 | 610 |
It started in 2010 to help people with kidney problems in India. It began as a small company and has now become one of the country’s most trusted kidney-care providers. The company has grown because it focuses on quality, careful planning, and clear strategies for expansion. It uses global best practices while adjusting its services to meet the needs of Indian patients. It keeps high standards for safety, cleanliness, and accurate medical care. In 2026, its share price target would be ₹1010, as per stock market analysts.
Its share price would be between ₹578 to ₹1010 in 2026, as per stock market analysts.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2026 | 578 | 1010 |
| महीना | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| जनवरी | 578 | 680 |
| फ़रवरी | 600 | 765 |
| मार्च | 651 | 788 |
| अप्रैल | 687 | 821 |
| मई | 712 | 845 |
| जून | 732 | 862 |
| जुलाई | 750 | 892 |
| अगस्त | 768 | 914 |
| सितंबर | 821 | 928 |
| अक्टूबर | 858 | 941 |
| नवंबर | 887 | 984 |
| दिसम्बर | 910 | 1010 |
It is widely present across India. The company runs many dialysis clinics; it is one of the largest kidney-care networks in the country. Its centres are placed in big cities as well as smaller towns that did not have access to kidney treatment before. This helps thousands of patients get regular and affordable dialysis without travelling far. The growing network shows the company’s strong planning, management skills, and commitment to providing quality care to people everywhere. In 2027, its share price target would be ₹1514, as per stock market analysts.
Its share price would be between ₹990 to ₹1514 in 2027, as per stock market analysts.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2027 | 990 | 1514 |
It treats a large number of patients every year, showing both the rise of kidney disease and the trust patients have in its services. Its clinics perform millions of dialysis sessions. Handling so many patients’ needs requires trained staff, advanced equipment, and well-organised processes. It helps to meet the growing demand for dialysis in India. High patient numbers also allow the company to improve its processes and keep costs reasonable for patients. In 2028, its share price target would be ₹2110, as per stock market analysts.
Its share price would be between ₹1455 to ₹2110 in 2028, as per stock market analysts.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2028 | 1455 | 2110 |
Instead of building large hospitals everywhere, it works with existing medical facilities or forms partnerships to set up dialysis units. This allows the company to expand quickly while keeping high quality. It also reduces costs and helps the company enter new areas faster. It keeps its operation simple and efficient. In 2029, its share price target would be ₹2651, as per stock market analysts.
Its share price would be between ₹2074 to ₹2651 in 2029, as per stock market analysts.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2029 | 2074 | 2651 |
It runs special clinics for different kidney problems, like diabetes-related kidney disease, high blood pressure-related kidney problems, inherited kidney conditions, glomerular diseases, and kidney stones. These clinics give focused care for each condition, with full evaluations and personalised treatment plans. Special clinics are important because kidney problems develop differently depending on the cause. With these clinics, patients get early diagnosis, better monitoring, and treatment that slows the disease. In 2030, its share price target would be ₹3230, as per stock market analysts.
Its share price would be between ₹2600 to ₹3230 in 2030, as per stock market analysts.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2030 | 2600 | 3230 |
| महीना | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| जनवरी | 2600 | 2774 |
| फ़रवरी | 2678 | 2790 |
| मार्च | 2710 | 2812 |
| अप्रैल | 2725 | 2832 |
| मई | 2745 | 2865 |
| जून | 2765 | 2890 |
| जुलाई | 2778 | 2922 |
| अगस्त | 2810 | 2956 |
| सितंबर | 2825 | 2982 |
| अक्टूबर | 2835 | 3024 |
| नवंबर | 2910 | 3125 |
| दिसम्बर | 3014 | 3230 |
The company also provides other health services like lab tests, imaging, heart care, pharmacy support, and wellness programs. People with kidney disease often need regular tests and medicines. It makes treatment easier and more organised. Patients don’t have to visit many places, and doctors can better track their health. This helps patients get better care and build trust with healthcare professionals who know their full health history. In 2040, its share price target would be ₹7241, as per stock market analysts.
Its share price would be between ₹6630 to ₹7241 in 2040, as per stock market analysts.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2040 | 6630 | 7241 |
| महीना | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| जनवरी | 6648 | 6789 |
| फ़रवरी | 6684 | 6820 |
| मार्च | 6721 | 6848 |
| अप्रैल | 6745 | 6868 |
| मई | 6765 | 6890 |
| जून | 6785 | 6925 |
| जुलाई | 6821 | 6952 |
| अगस्त | 6852 | 6987 |
| सितंबर | 6887 | 7025 |
| अक्टूबर | 6911 | 7085 |
| नवंबर | 6978 | 7125 |
| दिसम्बर | 7025 | 7241 |
India has more people getting diseases like diabetes and high blood pressure, which increase kidney problems. This creates a bigger need for dialysis services. It works to meet this need by opening clinics in areas that need them most, offering affordable care, and maintaining good treatment quality. The company also focuses on early detection, patient education, and long-term care, which helps reduce complications and supports national health efforts to fight kidney disease. In 2050, its share price target would be ₹15541, as per stock market analysts.
Its share price would be between ₹13510 to ₹15541 in 2050, as per stock market analysts.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2050 | 13510 | 15541 |
| महीना | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| जनवरी | 13510 | 13848 |
| फ़रवरी | 13625 | 13932 |
| मार्च | 13788 | 14088 |
| अप्रैल | 13825 | 14178 |
| मई | 13925 | 14238 |
| जून | 14044 | 14457 |
| जुलाई | 14224 | 14684 |
| अगस्त | 14457 | 14848 |
| सितंबर | 14525 | 15115 |
| अक्टूबर | 14754 | 15257 |
| नवंबर | 14957 | 15384 |
| दिसम्बर | 15125 | 15541 |
Should I buy Nephrocare Health Services stock?
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2025 | 300 | 610 |
| 2026 | 578 | 1010 |
| 2027 | 990 | 1514 |
| 2028 | 1455 | 2110 |
| 2029 | 2074 | 2651 |
| 2030 | 2600 | 3230 |
| 2040 | 6630 | 7241 |
| 2050 | 13510 | 15541 |
The company is one of India’s largest dialysis providers, with many clinics and a simple, low-cost business model, which could help it grow as more people need kidney care. But it only focuses on kidney services, and its financial details are not fully clear, so the stock price may go up and down, and there could be risks from rules or payment delays. For long-term investors who can take some risk, it may be a good option.
Nephrocare Health Services earnings results (Financials)
| अवधि समाप्त | 30 Sep 2025 | 31 मार्च 2025 | 31 मार्च 2024 | 31 मार्च 2023 |
| संपत्ति | 1,193.68 | 996.46 | 806.02 | 666.23 |
| कुल आय | 483.97 | 769.92 | 574.72 | 443.26 |
| कर के बाद लाभ | 14.23 | 67.10 | 35.13 | -11.79 |
| EBITDA | 110.31 | 166.64 | 99.66 | 48.60 |
| NET Worth | 716.06 | 594.21 | 423.55 | 384.73 |
| रिजर्व और अधिशेष | 704.14 | 578.68 | 408.57 | 383.50 |
| कुल उधार | 207.04 | 225.80 | 243.37 | 196.21 |
| राशि ₹ करोड़ | ||||
Is Nephrocare Health Services stock good to buy? (bull case & bear case)
बुल केस:
- In FY25 (March 2025), the company earned a total income of ₹769.92 crore, which is about 34% higher than ₹574.72 crore in FY24.
- Its Profit After Tax (PAT) for FY25 was ₹67.10 crore, almost double the ₹35.13 crore in FY24, showing strong profit growth.
- The company’s EBITDA was ₹166.64 crore in FY25, up from ₹99.66 crore in FY24, which means it is earning more from its core business and managing costs well.
- Its Net Worth increased to ₹594.21 crore in FY25 from ₹423.55 crore in FY24, indicating stronger financial health and shareholder value.
- Total Borrowings decreased slightly to ₹225.80 crore in FY25 from ₹243.37 crore in FY24, showing that the company is controlling its debt better.
- The company’s assets grew to ₹996.46 crore in FY25 from ₹806.02 crore in FY24, reflecting the expansion of clinics and infrastructure.
भालू का मामला:
- Profit After Tax (PAT) for Q2 FY26 (September 2025) fell to ₹14.23 crore from ₹67.10 crore in March 2025, showing that earnings fluctuate between quarters.
- Total income for September 2025 was ₹483.97 crore, lower than the full-year figure for March 2025, highlighting possible revenue volatility.
- Despite improvements, its debts are still ₹225.80 crore, which could pressure cash flow if costs rise or payments are delayed.
- The company mainly focuses on dialysis and kidney care, so it is not very diversified. Any changes in demand, competition, or regulations could hurt revenue.
निष्कर्ष
It is a top kidney-care company that provides dialysis in clinics, at home, and through mobile units, along with wellness support and small pharmacy services. It was started in 2009 in Hyderabad by Vikram Vuppala and Kamal Shah and has grown into one of the largest dialysis providers in India and Asia, with clinics in big cities, smaller towns, and countries like the Philippines, Uzbekistan, and Nepal. The company uses systems like RenAssure and Renova to make treatment safe and high-quality. It mainly focuses on kidney care, and earnings can change, so there are some risks. Overall, it is well set for long-term growth in kidney healthcare.
